Bristol-Myers Squibb Company (BMY) Financials
PeriodQ2 FY2026
Published
Bristol-Myers Squibb reported $12.97 billion in total revenues for Q2 FY2026, the quarter ended June 30, 2026, up 5.7% from a year earlier, and net earnings attributable to the company of $3.32 billion, up 153.2%. Diluted earnings per share were $1.62 against $0.64 a year earlier, though most of that earnings increase came from expenses that did not repeat rather than from the top line: Bristol-Myers Squibb recorded no acquired in-process research and development charge in the quarter, against a large one a year earlier, and amortization of acquired intangible assets fell sharply. Growth Portfolio revenue reached $7.56 billion, up 14.6%, while Eliquis, the company's largest single product and the only separately reported brand in its shrinking Legacy Portfolio to grow, contributed $4.48 billion, up 21.8%, on higher demand and higher realized U.S. net selling prices after a list price reduction cut rebates. Alongside the results, Bristol-Myers Squibb raised its full-year 2026 revenue and non-GAAP earnings per share guidance.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $12,973,000,000 | up 5.7% |
| Net earnings | $3,317,000,000 | up 153.2% |
| Diluted EPS | $1.62 | up 153.1% |
| Growth Portfolio revenue | $7,560,000,000 | up 14.6% |
| Eliquis revenue | $4,481,000,000 | up 21.8% |
Company details
| Name | Bristol Myers Squibb Co |
|---|---|
| Ticker | BMY |
| CIK | 0000014272 |
| Exchange | NYSE |
| State | New Jersey |
| Incorporation | Delaware |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 10-Q, accession 0000014272-26-000020 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 10-Q around 2026-10-29 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Bristol-Myers Squibb Q2 FY2026
How much revenue did Bristol-Myers Squibb report in Q2 FY2026?
Bristol-Myers Squibb reported $12.97 billion in total revenues for Q2 FY2026, the quarter ended June 30, 2026. That is up 5.7% from $12.27 billion in the same quarter a year earlier.
What was Bristol-Myers Squibb's earnings per share in Q2 FY2026?
Bristol-Myers Squibb reported diluted earnings per share of $1.62 for Q2 FY2026, against $0.64 in the same quarter a year earlier, on net earnings attributable to the company of $3.32 billion.
Why did Bristol-Myers Squibb's net income rise in Q2 FY2026?
Net earnings attributable to Bristol-Myers Squibb were $3.32 billion in Q2 FY2026 against $1.31 billion a year earlier, but the increase came mainly from charges that did not repeat. The company recorded no acquired in-process research and development charge in the quarter, against a large one a year earlier, and amortization of acquired intangible assets fell sharply, which cut total expenses even as revenue grew.
How much Eliquis revenue did Bristol-Myers Squibb report in Q2 FY2026?
Eliquis generated $4.48 billion of revenue for Bristol-Myers Squibb in Q2 FY2026, up 21.8% from $3.68 billion a year earlier. Eliquis sits in Bristol-Myers Squibb's Legacy Portfolio and remains its largest single product, while the whole Growth Portfolio generated $7.56 billion in the same quarter.
Where can I get Bristol-Myers Squibb Company (BMY) financial data in machine-readable form?
Ticker Scout publishes Bristol-Myers Squibb Company's financial statements as JSON at https://tickerscout.ai/bmy/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/bmy/narrative.md and https://tickerscout.ai/bmy/events.md. Bristol-Myers Squibb Company's SEC CIK is 0000014272. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Bristol-Myers Squibb Company (BMY) next file with the SEC?
Bristol-Myers Squibb Company (BMY) is expected to file its next Form 10-Q with the SEC on or around October 29, 2026. That date is a projection rather than a company-announced date: it is derived from Bristol-Myers Squibb Company's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0000014272-26-000020.
Related companies
How this page was built
This page was built from Bristol-Myers Squibb Company's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names six such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.